. 2021 Sep 8;16(9):e0256980. doi: 10.1371/journal.pone.0256980

Table 2. Immunized cohort CA (solicited AEs): Numbers of volunteers experiencing local, and systemic adverse events (days 0–7 post each immunization)^1,2.

Sign or Symptom	DNA 1 (n = 20) (% of vol’s)		DNA 2 (n = 20) (% of vol’s)		DNA 3 (n = 20) (% of vol’s)		ChAd (n = 19) (% of vol’s)		Total AE’s (% of all AE’s)
	Gr1	Gr2/3	Gr1	Gr2/3	Gr1	Gr2/3	Gr1	Gr2/3
LOCAL
Ecchymosis	3(15%)	0	4(20%)	0	4(20%)	0	2(11%)³	0	14(14%)
Induration	0	0	0	0	0	0	0	0	0
Pain	4(20%)	0	5(25%)	1(5%)	7(35%)	0	5(26%)	2(11%)	29(28%)
Parasthesia	0	0	0	0	0	0	0	0	0
Pruritus	1(5%)	0	2(10%)	1(5%)	2(10%)	0	0	0	6(6%)
Redness	0	0	0	0	0	0	0	0	0
Scaling	0	0	0	0	1(5%)	0	0	0	1(1%)
Swelling	0	0	0	0	0	0	0	0	0
Tenderness	9(45%)	0	11(55%)	1(5%)	7(35%)	0	9(47%)	2(11%)³	45(44%)
Warmth	2(10%)	0	3(15%)	0	1(5%)	0	0	0	7(7%)
Total Local AEs	24	0	33	3	22	0	16	4	102 (55%)
SYSTEMIC
Abdominal Pain	0	0	0	0	0	0	1(5%)	1(5%)	2(2%)
Arthralgia	1(5%)	0	0	0	0	0	1(5%)	1(5%)³	3(4%)
Chills	0	0	0	0	0	0	1(5%)	6(32%)³	8(10%)
Cough	2(10%)	0	0	1(5%)	2(10%)	0	1(5%)	0	7(8%)
Diarrhea	0	0	0	0	0	0	0	0	0
Dizziness	0	0	0	0	0	0	2(11%)	2(11%)³	4(5%)
Fatigue	0	1(5%)	2(10%)	1(5%)	0	0	4(21%)	6(32%)⁵	15(18%)
Fever	0	0	0	0	0	0	2(11%)	1(5%)³	3(4%)
Flu-like illness	0	0	0	1(5%)	1(5%)	1(5%)	1(5%)	3(16%)³	7(8%)
Headache	2(10%)	0	2(10%)	0	0	1(5%)	3(15%)	5(26%)³	14(17%)
Malaise	0	0	0	0	0	0	2(11%)	4(21%)³	6(7%)
Myalgia	2(10%)	1(5%)	0	0	0	0	1(5%)	3(16%)³	9(11%)
Nausea	1(5%)	0	0	0	0	1(5%)	0	1(5%)⁴	3(4%)
Regional adenopathy	0	0	0	0	0	0	0	0	0
Rigors	0	0	0	0	0	0	1(5%)	0	1(1%)
Vomiting	0	0	0	0	0	0	0	1(5%)⁴	1(1%)
Total Systemic AEs	11	4	4	3	3	3	21	34	83(45%)
Total All AEs	35	4	37	6	25	3	37	38	185(100%)

Table 2. Immunized cohort CA (solicited AEs): Numbers of volunteers experiencing local, and systemic adverse events (days 0–7 post each immunization)1,2.